CN116210912A - 预防中风和老年痴呆的组方及制备方法 - Google Patents
预防中风和老年痴呆的组方及制备方法 Download PDFInfo
- Publication number
- CN116210912A CN116210912A CN202310434936.4A CN202310434936A CN116210912A CN 116210912 A CN116210912 A CN 116210912A CN 202310434936 A CN202310434936 A CN 202310434936A CN 116210912 A CN116210912 A CN 116210912A
- Authority
- CN
- China
- Prior art keywords
- parts
- senile dementia
- phosphatidylserine
- gamma
- aminobutyric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 32
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 32
- 208000006011 Stroke Diseases 0.000 title claims abstract description 30
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 42
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 42
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 25
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 25
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 21
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 21
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 21
- 235000010447 xylitol Nutrition 0.000 claims abstract description 21
- 239000000811 xylitol Substances 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 21
- 229960002675 xylitol Drugs 0.000 claims abstract description 21
- 241000723353 Chrysanthemum Species 0.000 claims abstract description 18
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 239000000654 additive Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 244000113306 Monascus purpureus Species 0.000 claims description 5
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 5
- 229940057059 monascus purpureus Drugs 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 9
- 230000015654 memory Effects 0.000 abstract description 8
- 230000003925 brain function Effects 0.000 abstract description 6
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 208000029028 brain injury Diseases 0.000 abstract description 4
- 230000003727 cerebral blood flow Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 229940026314 red yeast rice Drugs 0.000 abstract description 3
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- -1 red yeast rice Chemical compound 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 10
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000007189 Oryza longistaminata Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000005978 brain dysfunction Effects 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000572565 Alpinia oxyphylla Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了预防中风和老年痴呆的组方及制备方法，按重量份计包含以下组份：磷脂酰丝氨酸1‑3份，红曲10‑15份，γ‑氨基丁酸0.1‑1份，菊花3‑6份，益智仁2‑5份，添加剂2‑5份；本发明将磷脂酰丝氨酸、红曲、γ‑氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙制成坚实型压片糖果，提高大脑机能，集中注意力，改善记忆力；帮助修复大脑损伤，能够促进脑血流增加氧气供给，促进脑代谢，对保护心血管、预防冠心病、中风、老年痴呆颇有裨益；还能有效改善大脑机能，补脑益智，增强记忆力。
Description
技术领域
本发明涉及保健食品技术领域，具体为预防中风和老年痴呆的组方及制备方法。
背景技术
神经系统疾病发生于中枢神经系统、周围神经系统、植物神经系统的以感觉、运动、意识、植物神经功能障碍为主要表现的疾病。
神经系统遭受损伤时正常功能丧失，此即缺失症状。神经系统疾病的症状体征可表现为意识障碍、感知觉障碍、运动障碍。
现在迫切需要的是在正确的帕金森氏症的分子病理学机制的基础上，开发一种针对神经保护治疗的药物，它能够预防或者延缓疾病的发展并且能够改善各种程度的神经退行性脑功能紊乱以及帕金森氏症的老年痴呆症状；现有技术采用左旋多巴(L-多巴)以改善伴随帕金森氏症的老年痴呆患者的认知功能的方法尚未大规模的使用，但是并不能延迟认知功能退化；因此本申请提出了一种预防中风和老年痴呆的组方，能够预防或者延缓疾病的发展，并且能够改善各种程度的神经退行性脑功能紊乱以及帕金森氏症的老年痴呆症状。
发明内容
本发明的目的在于提供预防中风和老年痴呆的组方及制备方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：预防中风和老年痴呆的组方，按重量份计包含以下组份：磷脂酰丝氨酸1-3份，红曲10-15份，γ-氨基丁酸0.1-1份，菊花3-6份，益智仁2-5份，添加剂2-5份。
其中，所述添加剂按重量份计包含以下组份：木糖醇0.5-3份，维生素C0.5-3份，微晶纤维素0.1-0.5份，轻质碳酸钙0.1-0.5份。
其中，预防中风和老年痴呆的组方的制备方法，包括以下步骤：
S1、按重量份分别称取磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙，以备后续使用；
S2、将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙均匀混合在一起，得到混合原料；
S3、通过压片机将混合原料进行压片处理，得到预防中风和老年痴呆的片剂。
其中，所述预防中风和老年痴呆的片剂每日食用量≤3g，所述磷脂酰丝氨酸每日食用量≤600mg，所述γ-氨基丁酸每日食用量≤500mg，所述微晶纤维素每日食用量≤60mg，所述轻质碳酸钙每日食用量≤60mg。
磷脂酰丝氨酸的主要功效如下：1、提高大脑机能，集中注意力，改善记忆力。补充磷脂酰丝氨酸后，关于认知和记忆的参数得到显著改善。所以补充磷脂酰丝氨酸可以提高长期记忆、长期认知以及自由谈吐和逻辑性发言能力；2、提高学生成绩；3、缓解压力，促进用脑疲劳的恢复、平衡情绪。多项研究表明，磷脂酰丝氨酸能显著降低工作紧张者体内过多的应激激素的水平，减轻压力，缓解脑部疲劳；4、帮助修复大脑损伤。磷脂酰丝氨酸是脑部神经的主要成分之一，可营养和活化脑中各种酶的活性，能延缓神经递质的减少进程，有助于修复、更新大脑受损细胞和清除有害物质。
红曲是曲霉科真菌的菌丝体寄生在粳米上形成的红曲米，并且它的最好采摘时间为夏天下雨过或者细雨天。红曲作为中药材，它不具有毒性，既可以熬成汤喝进肚子里内调，也可以外敷伤口处。红曲除了具有降三高的功效，还能活血化瘀、健脾消食。
γ-氨基丁酸作为抑制性神经递质，它具有醒脑作用，它可以改善脑血流流通，增加氧的供给，促进脑的代谢功能，可用于治疗因中风、头外伤后遗症，以及脑血管硬化后遗症等产生的头痛、耳鸣、意识障碍等病症，并对改善肝脏肾脏的功能有一定作用。它可以有降压作用，它能够促进脑血流增加氧气供给，促进脑代谢；另外作用于饮水的脑血管中枢，使血压下降，同时抑制抗利尿激素的分泌，扩张血管，降低血压。
菊花具有祛散风热、清热明目、平肝解毒的功效，用于外感风热感冒所致头疼、身热、目赤肿痛、视物昏花、头晕目眩，痈肿疮毒。
益智仁具有温暖脾肾的作用，温脾可以治疗脾虚引起的腹痛、腹泻；温肾可以固精，可以缩尿，治疗夜间的遗尿；还可以促进人体的新陈代谢，增强记忆。
木糖醇中含有多种对人体有益的微量元素，且它含有的某些成分在进入人体后，还能转化成人体正常代谢时，必须的益生菌能促进人体内抗体产生，也能增强人体免疫细胞的活性，它对增强人体自身免疫能力有极大好处，而那些处于发育期的青少年在食用木糖醇后还能促进身体发育，提高身体健康水平。
维生素C的作用有：1、抑制黑色素的生长和增加，有很好的祛斑效果；2、有抗氧化的功效，延缓衰老；3、可以改善铁和叶酸的吸收，预防一些心脑血管疾病出现。
微晶纤维素采用食品级微晶纤维素，在食品中可以增加肠胃的消化能力，可以增加排便功能。
轻质碳酸钙采用食品级轻质碳酸钙，作为一种膨松剂。
与现有技术相比，本发明的有益效果是：
本发明将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙制成坚实型压片糖果，提高大脑机能，集中注意力，改善记忆力；帮助修复大脑损伤，能够促进脑血流增加氧气供给，促进脑代谢，对保护心血管、预防冠心病、中风、老年痴呆颇有裨益；还能有效改善大脑机能，补脑益智，增强记忆力。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
预防中风和老年痴呆的组方，按重量份计包含以下组份：磷脂酰丝氨酸1份，红曲10份，γ-氨基丁酸0.1份，菊花3份，益智仁4份，木糖醇1份，维生素C1份，微晶纤维素0.1份，轻质碳酸钙0.1份。
预防中风和老年痴呆的组方的制备方法，包括以下步骤：
S1、按重量份分别称取磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙，以备后续使用；
S2、将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙均匀混合在一起，得到混合原料；
S3、通过压片机将混合原料进行压片处理，得到预防中风和老年痴呆的片剂。
实施例2
预防中风和老年痴呆的组方，按重量份计包含以下组份：磷脂酰丝氨酸1份，红曲15份，γ-氨基丁酸0.1份，菊花3份，益智仁4份，木糖醇1份，维生素C1份，微晶纤维素0.1份，轻质碳酸钙0.1份。
预防中风和老年痴呆的组方的制备方法，包括以下步骤：
S1、按重量份分别称取磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙，以备后续使用；
S2、将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙均匀混合在一起，得到混合原料；
S3、通过压片机将混合原料进行压片处理，得到预防中风和老年痴呆的片剂。
实施例3
预防中风和老年痴呆的组方，按重量份计包含以下组份：磷脂酰丝氨酸1份，红曲10份，γ-氨基丁酸0.1份，菊花6份，益智仁4份，木糖醇1份，维生素C1份，微晶纤维素0.1份，轻质碳酸钙0.1份。
预防中风和老年痴呆的组方的制备方法，包括以下步骤：
S1、按重量份分别称取磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙，以备后续使用；
S2、将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙均匀混合在一起，得到混合原料；
S3、通过压片机将混合原料进行压片处理，得到预防中风和老年痴呆的片剂。
实验例
根据自愿原则，选取200位45-65岁患者，其中：中风后遗症50例、脑萎缩、脑瘫50例、帕金森病50例，老年痴呆、健忘50例。
使用方法：口服本申请实施例1制备的片剂，服法用量：每天一次，每次一粒(3g)，持续服用49天；治疗效果见下表。
由上表可以看出，中风后遗症、脑萎缩、脑瘫、帕金森病、老年痴呆、神经官能症、失眠、健忘等症状得以缓解和减轻，有明显的食补治疗效果，本申请将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙制成坚实型压片糖果，提高大脑机能，集中注意力，改善记忆力；帮助修复大脑损伤，能够促进脑血流增加氧气供给，促进脑代谢，对保护心血管、预防冠心病、中风、老年痴呆颇有裨益；还能有效改善大脑机能，补脑益智，增强记忆力。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (4)
1.预防中风和老年痴呆的组方，其特征在于，按重量份计包含以下组份：磷脂酰丝氨酸1-3份，红曲10-15份，γ-氨基丁酸0.1-1份，菊花3-6份，益智仁2-5份，添加剂2-5份。
2.根据权利要求1所述的预防中风和老年痴呆的组方，其特征在于，所述添加剂按重量份计包含以下组份：木糖醇0.5-3份，维生素C 0.5-3份，微晶纤维素0.1-0.5份，轻质碳酸钙0.1-0.5份。
3.预防中风和老年痴呆的组方的制备方法，其特征在于，包括以下步骤：
S1、按重量份分别称取磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙，以备后续使用；
S2、将磷脂酰丝氨酸、红曲、γ-氨基丁酸、菊花、益智仁、木糖醇、维生素C、微晶纤维素和轻质碳酸钙均匀混合在一起，得到混合原料；
S3、通过压片机将混合原料进行压片处理，得到预防中风和老年痴呆的片剂。
4.根据权利要求3所述的预防中风和老年痴呆的组方的制备方法，其特征在于，所述预防中风和老年痴呆的片剂每日食用量≤3g，所述磷脂酰丝氨酸每日食用量≤600mg，所述γ-氨基丁酸每日食用量≤500mg，所述微晶纤维素每日食用量≤60mg，所述轻质碳酸钙每日食用量≤60mg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310434936.4A CN116210912A (zh) | 2023-04-21 | 2023-04-21 | 预防中风和老年痴呆的组方及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310434936.4A CN116210912A (zh) | 2023-04-21 | 2023-04-21 | 预防中风和老年痴呆的组方及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116210912A true CN116210912A (zh) | 2023-06-06 |
Family
ID=86575280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310434936.4A Withdrawn CN116210912A (zh) | 2023-04-21 | 2023-04-21 | 预防中风和老年痴呆的组方及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116210912A (zh) |
-
2023
- 2023-04-21 CN CN202310434936.4A patent/CN116210912A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703134B (zh) | 一种保健茶 | |
| CN101612255A (zh) | 一种清脂茶的配方及其制备方法 | |
| CN101700365A (zh) | 一种改善视力的功能性饮料 | |
| CN105902922A (zh) | 一种具有解酒护肝功能的组合物及其制备方法 | |
| CN109820905A (zh) | 一种治疗失眠的药物组合物及其应用 | |
| CN106563099A (zh) | 一种解酒护肝口服液 | |
| CN114041593A (zh) | 一种降尿酸的复合寡糖酵素酶及其制备方法 | |
| CN101380128A (zh) | 竹葵多功能保健饮料及制法 | |
| CN105249440A (zh) | 一种阿胶糕 | |
| CN109793075A (zh) | 一种蔓越莓果茶营养配方 | |
| CN103960426A (zh) | 一种中药减肥茶 | |
| CN104694315B (zh) | 一种防衰老葡萄酒及制备方法 | |
| CN114569686B (zh) | 一种解酒组合物、具有解酒功效的片剂及其制备方法 | |
| CN116210912A (zh) | 预防中风和老年痴呆的组方及制备方法 | |
| CN116114887A (zh) | 一种复合型双蛋白组合物及其制备方法 | |
| CN110692983A (zh) | 一种燕窝梨膏制备方法 | |
| CN109432346A (zh) | 一种健康养生酒的制作及方法 | |
| CN103829342A (zh) | 功能性保健饮料及其制备方法 | |
| CN114788556A (zh) | 一种解酒枸杞茶醋饮料及其制备方法 | |
| CN101756178A (zh) | 营养口服液及其制备方法 | |
| CN106085769A (zh) | 一种营养保健酒及其制备方法 | |
| CN111513157A (zh) | 一种含枸杞决明子的养生茶及其制作方法 | |
| CN1698800A (zh) | 一种保护眼睛的药酒 | |
| CN110507707A (zh) | 一种治疗ⅱ型糖尿病的中药组合物及其制备方法 | |
| CN109619479A (zh) | 一种具有缓解视疲劳的山楂制品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230606 |
|
| WW01 | Invention patent application withdrawn after publication |